Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:

) is one of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and twelve months ended December 31, 2025, on February 26, 2026. It reported that total revenue for the three and twelve months was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million in the prior year periods, respectively.

Net product sales of LUPKYNIS, which is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $74.2 million and $271.3 million for the three and twelve months, up 29% and 25%, respectively, compared to $57.6 million and $216.2 million for the same periods of 2024, respectively.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) further reported that it has cash, cash equivalents, restricted cash, and investments of $398.0 million as of December 31, 2025, compared to $358.5 million in the prior year period. It also repurchased 12.2 million of its common shares for $98.2 million in the year 2025. For 2026, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) expects total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a clinical-stage bio-pharmaceutical company involved in the research, development, and commercialization of therapeutic drugs.